Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
HORSHAM, Pa., July 15 /PRNewswire/ -- Based on the data presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of trabectedin when administered with DOXIL(R) (doxorubicin HCI liposome injection) did not provide a...
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known a...
Rituximab maintenance therapy improves survival in patients with relapsed follicular lymphoma
Patients with relapsed
or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal ...
Drug combination improves or stabilizes disease for relapsed multiple myeloma patients
ROCHESTER, Minn. -- Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed
after previous treatment.
Interim results of an ongoing clinical trial evaluati...
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
SEATTLE, Dec. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) announced today that the results of three Italian
multicenter studies utilizing Zevalin(R) ([90Y]-ibritumomab tiuxetan) were
presented at the American Society of Hematology (ASH) 50th Annual Meeting in
Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
BRIDGEWATER, N.J., Nov. 20 /PRNewswire/ -- Ortho Biotech Products, L.P. today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treat...
Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
TREANDA Receives Second Indication this Year; Data Demonstrate High,
Durable Response Rates for Patients with indolent NHL Who Have Progressed
Following a Rituximab-Containing Regimen
FRAZER, Pa., Nov. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq:
CEPH) today announced that the U.S. F...
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
TREANDA Receives Second Indication this Year; Data Demonstrate High,
Durable Response Rates for Patients with indolent NHL Who Have Progressed Following a Rituximab-Containing Regimen
FRAZER, Pa., Oct. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq:
CEPH) today announce...
Clinical study shows biological and clinical activity in relapsed leukemia patients
LUGANO, SWITZERLAND, June 4, 2008 Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Confere...
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that data from the
Phase III trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in
combination with cytarabine in patients with first relapse of acute
myelogenous leukemia ...
relapsed in Medical Technology
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed
acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show th...
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Feb. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) announced today that updated safety and efficacy data
from the phase III trial of pixantrone provides further support for a robust
clinical benefit for pixantrone when used as single agent therapy in the
Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial
SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI)
(Nasdaq and MTA: CTIC) announced today preliminary progression-free survival
(PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone
that show patients with advanced, relapsed
aggressive non-Hodgkin's lymph...
Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
First T cell engaging antibody (BiTE) showing clinical benefit in cancer
patients; Blinatumomab enables patients own T cells to recognize and attack cancer cells
BETHESDA, Md., Aug. 14 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ), a biopharmaceutical c...
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Study Reports 92 Percent Response Rate to Combination Treatment
FRAZER, Pa., July 15 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) announced today that in a phase 2 study published online today in the
Journal of Clinical Oncology, 92 percent of patients with relapsed
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Provides Update on Carfilzomib Development Program in Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc.
today announced that patient dosing has commenced in a Phase 1b clinical
trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
Interim Phase 1 Data Presented at International Conference on Malignant Lymphomas Shows Dose Dependent Single Agent Activity
BETHESDA, Md., June 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq:
MITI), a biopharmaceutical company developing novel, proprietary antibodies
for the trea...
Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire/ -- Proteolix, Inc.
today announced that patient dosing has commenced in a Phase 2 clinical
trial of carfilzomib (PR-171), a selective blocker of proteasome activity,
solid tumors. A Phase 1b dose-escalation trial of carfilzomib
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Results underscore promise of radioimmunotherapy in ASCT and warrant randomized trial
SEATTLE, Jan. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(CTI) (Nasdaq and MTAX: CTIC) announced today that results of a phase II
clinical study, published in the Journa...
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
BOULDER, Colo. and MONTREAL, Jan. 9 /PRNewswire-FirstCall/ -- Pharmion
Corporation (Nasdaq: PHRM ) and MethylGene Inc. (TSX: MYG) today announced
the enrollment of the first patient in a Phase 2 clinical trial (Trial
CL002) evaluating MGCD0103, the Companies' isotype-selective histone
relapsed in Medical Dictionary
...hood Acute Lymphoblastic Leukemia ... ACUTE LYMPHOBLASTIC LEUKEMIA OVERVIEW Acute lymphoblastic leukemia (ALL) is a ... Treatment of relapsed
or refractory acute lymphoblastic leukemia in adults ... Review Article from The New England Journal of Medicine -- Acute Lymphoblastic ...
relapsed in Biological News
St. Jude identifies genomic causes of a certain type of leukemia relapse
...ant problem, with only 30 percent of children with relapsed
Previous studies had found some ...osts to pinpoint genetic changes characteristic of relapsed
cells. Using these genetic markers, the researcher...anges called copy number abnormalities specific to relapsed
cells. These changes are considered a major type o...
Promising new treatment option for women with recurrent ovarian cancer
...ith pegylated liposomal doxorubicin provides clinical benefit to women with relapsed
ovarian cancer, according to new results presented at the 33rd Congress of ...red to 5.8 months for those treated with the single drug. For those who had relapsed
more than six months after the first-line therapy, the median progression-f...
Galiximab in combination with rituximab in patients with previously untreated follicular lymphoma
...liximab is an anti-CD80 monoclonal antibody that has been studied as a single-agent in previously treated FL and in combination with rituximab against relapsed
FL. The CD80 molecule is found on the surface of activated macrophages, dendritic cells and cells from various subtypes of NHL. Galiximab's potential ...
Investigating the measles virus as a tool to kill multiple myeloma
...ectively irradiate cancer cells, image the tumors and monitor regression.
Eligible candidates for the multiple myeloma study will be adults with relapsed
or refractory (that is, having had more than one type of treatment fail them) myeloma. They must not have had allogeneic (from another person) stem ce...
Successful lung cancer surgery not enough to break nicotine dependence in many smokers
...tients quit before surgery may have been influenced by their "self efficacy" for quitting, he says. "The thing that really drove whether or not people relapsed
is whether they saw smoking as pleasurable and rewarding to the point that they can’t do without cigarettes, and they don’t believe they are able to q...
Compound from marine bacteria shows potential as multiple myeloma therapy
...ype of blood cancer and accounts for 11,000 deaths annually in the United States. Bortezomib, approved by the Food and Drug Administration in 2003 for relapsed
myeloma patients and subsequently for patients who have received at least one prior treatment, demonstrated in clinical trials that it extended the ti...
Hepatitis C responds best to combo of ribavirin and interferon, study concludes
...hepatitis C for more than six months and were previously untreated, who had relapsed
after treatment or who had not responded to other treatment.
The review ... percent of those getting interferon plus ribavarin.
Among those who had relapsed
after previous treatment 87 percent of interferon-only patients did not res...
NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
...ficant because these patients had not responded to standard treatments or chemotherapies used in treating patients with melanoma.
Thirteen patients relapsed
after positive response to therapy and developed tumors at pre-existing or new sites within the body. There were no treatment-related deaths in this s...
Potential Cure for Lymphoma in HIV patients
... Stem cell transplants have become the
standard of care for patients with relapsed
lymphoma, but not for
patients who suffer from both this disease and HIV. A...erapy soon after
discharge from the hospital.
Although two patients died of relapsed
lymphoma a few months after
transplant, 17 of the 20 patients (85 percent) ...
relapsed in Biological Technology
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL
ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ --
Intent to treat Analysis results per FDA agreed upon Statistical Analysis Plan
Significant Increase in Complete Rem...
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
FRAZER, Pa., Dec. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) today announced that it has submitted a New Drug Application (NDA) to
the U.S. Food and Drug Administration (FDA) requesting approval of
TREANDA(R) (bendamustine HCl) for Injection for the treatment of patients
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
...al to continue to advance pixantrone to market."
Completed the submission of the pixantrone NDA to the FDA to treat relapsed
or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI requested priority review of the pixantrone NDA which, if granted, could lead to an approva...
AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
...hway inhibitor compound, perifosine (KRX-0401), in relapsed
or relapsed/refractory multiple myeloma patients p...t 90%, will enroll approximately 400 patients with relapsed
or relapsed/refractory multiple myeloma. The prima...d dexamethasone in approximately 400 patients with relapsed
or relapsed/refractory multiple myeloma. Patients ...
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
...treatment with rituximab or a rituximab-containing regimen and TRISENOX((R)) (arsenic trioxide) injection, approved for the treatment of patients with relapsed
or refractory acute promyelocytic leukemia.
In Europe, Cephalon markets three additional oncology products in 19 countries.
Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
...he Phase II study, 61 patients with late stage AML who failed to
respond or relapsed
after two separate rounds of treatments received
third-line therapy (also c...the outcome of the trial, Professor Giles said:
"Patients with refractory / relapsed
AML today have no standard therapy as
existing therapies are inadequate for...
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
... capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed
and refractory myeloma.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy...
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
...hematologic malignancies and solid tumors.
Multiple Myeloma Patients Achieve Responses with S...se 2 clinical trial of single-agent carfilzomib in relapsed
multiple myeloma patients. Patients in the study have relapsed
after receiving one to three prior therapies and a...
Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
...e the anti-tumor activity of cytarabine:daunorubicin, even in patients with relapsed
and refractory disease."
The first poster presented data on the pharma...okinetics and pharmacology of CPX-351 from a Phase I study of patients with relapsed
or refractory acute leukemias.(1) Evidence of antitumor effect, details of...
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
..., Phase I/II study of AT-101 in combination with topotecan in patients with relapsed
or refractory small cell lung cancer (SCLC) who had received prior platinum...ase I/II study of AT-101 in combination with topotecan (T) in patients with relapsed
or refractory small cell lung cancer (SCLC) after prior platinum containing...